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Abstract
Background and aim Hepatocellular carcinoma is one of
the major causes of death due to cancer worldwide, and its
association with hepatitis C virus infection has been
definitively established. Hepatitis C virus is also involved
in the pathogenesis of non-Hodgkin’s lymphoma. This is
the only virus infecting humans that is able to induce two
different malignancies. We analyzed the expression levels
of a panel of microRNA in peripheral blood mononuclear
cells of patients with hepatitis C virus-related malignancies
in order to find a disease-associated deregulation and
identify specific biomarkers.
Methods We tested peripheral blood mononuclear cells
isolated from patients with hepatocellular carcinoma, non-
Hodgkin’s lymphoma, hepatitis C virus without malig-
nancies and healthy subjects for a panel of microRNA
selected on the basis of previous studies. MicroRNA
expression was evaluated by real-time PCR.
Results Our results showed an upregulation of miRNA-
21 and downregulation of miRNA-26b in hepatocellular
carcinoma and non-Hodgkin’s lymphoma patients com-
pared to controls (p\ 0.001). Deregulation of miRNA-16
and miRNA-155 was limited to lymphoma patients.
Conclusions This study shows that some microRNAs are
differently expressed in peripheral blood mononuclear cells
from hepatitis C virus patients who develop hepatocellular
carcinoma or lymphoma, while others share a common
behavior. Thus, analysis of the expression of microRNAs
could be a noninvasive marker of hepatitis C virus-related
carcinogenesis. This analysis could be a suitable tool for
identifying the existence of a malignancy and also dis-
criminating between these two hepatitis C virus-related
cancers.
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Introduction
Hepatitis C virus (HCV) infection is a primary public
health problem with about 200 million HCV carriers
worldwide. Hepatocellular carcinoma (HCC) is a major
malignancy worldwide, being the second most frequent
cause of cancer death in males and the sixth in females [1].
HCV is responsible for 33 % of HCCs in developing
countries, and since no vaccine is available, the only
strategy to implement is prevention [1]. HCV is also
involved in the pathogenesis of non-Hodgkin’s lymphoma
(NHL) [2–4]. For these reasons, HCV is the only human
virus able to induce two different kinds of cancer.
The evolution of HCC may occur from the progress of
different stages of hepatitis and cirrhosis, while lymphoma
results from overexpanded B cell clones characterizing
mixed cryoglobulinemia (MC), a benign but prelym-
phomatous HCV-related lymphoproliferative disorder [5–
7]. The exact mechanisms by which HCV induces both
HCC and NHL remain undefined. Several reports have
demonstrated that HCV alters the expression of specific
oncogenes and tumor-suppressor genes implicated in car-
cinogenesis and/or lymphomagenesis [3, 4], and the host’s
genetic background also seems to play a role [8].
In the last 10 years, research interest has been focused
on a class of epigenetic post-transcriptional regulators, the
microRNAs (miRNAs). Acting on gene expression modu-
lation, the miRNAs are involved in the fine tuning of
physiological responses and make an important contribu-
tion to the pathogenesis of several diseases. Modifications
in specific miRNA patterns are correlated with several
types of human cancers and seem to play a role in different
aspects of carcinogenesis [9].
Numerous studies are available today regarding HCC,
several reporting unique profiles with only a few miRNAs in
common, suggesting that the pathophysiology of HCC is
complex and heterogeneous. So far, downregulation, mostly
in HCV-negative HCCs, has been described for miR-122, a
microRNA specific for the liver [10–12]. Also, less than
normal levels ofmiR-199a/b-3p, ofmembers of themiR-100
family (miR-100 and miR-99a) and of the let-7 family have
been reported in HCCs of different etiology, although the
opposite behavior was observed for let-7a and let-7f in viral-
negative HCCs [10, 11, 13]. MiR-21 is reported as the most
upregulated miRNA in HCC [14]: since one of its target
genes is the tumor-suppressor PTEN (phosphatase and tensin
homolog), miR-21 upregulation reflects lower PTEN
expression, contributing to HCC growth, migration and
invasion [14]. A recent paper has attributed to serum levels of
miR-1 andmiR-122 a predictive value for overall survival in
HCC of different etiologies, showing the importance of
miRNAs as biological markers [15].
Since miRNAs play a role in different stages of the
hematopoietic maturation process, they are implicated in
several blood malignancies and are correlated with prog-
nosis and phenotype. Several studies have confirmed the
involvement of cancer-related and newly identified miR-
NAs, namely miR-155, miR-146a, miR-21 and miR-26b, in
the pathogenesis of different subtypes of lymphomas
including some HCV-related ones (marginal zone lym-
phoma, MZL and diffuse large B cell lymphoma, DLBCL)
[16–19]. MiR-21 and miR-26b have also been associated
with the development of HCC and poor outcome after liver
cancer therapy, respectively [20, 21]. Notably, downregu-
lation of miR26b, previously shown in HCV-related NHL
[16], has been confirmed in patients with MC, suggesting
its involvement also in this prelymphomatous condition
[22].
However, the biological significance of miRNA dereg-
ulation in HCV-related HCC and lymphomas, together
with targets and biochemical mechanisms, needs to be
clarified. To date, there are no reliable diagnostics for
predicting the risk that chronic HCV infection will evolve
into HCC or NHL and, for this reason, there is increasing
interest in translational research able to enhance our
knowledge of this topic. In this light, in the present study
we have evaluated the expression levels of a panel of
selected miRNAs in peripheral blood mononuclear cells
(PBMCs) of patients with HCV-related malignancies, HCC
and NHL in order to clarify disease-associated deregulation
and identify novel specific biomarkers.
Patients and methods
Patients
We studied 125 HCV chronically infected patients with the
following characteristics: 85 with HCV-positive chronic
hepatitis (HCV), 15 with HCV-associated NHL (NHL-
HCV), 25 with HCV positive HCC (HCC-HCV) and 40
healthy blood donors (HS) as negative controls, referred to
the outpatient clinics of the MASVE Center of the
University of Florence and of the Department of Medical
and Surgical Sciences of the University of Bologna. The
main clinical, serological and virological data of subjects
are reported in Table 1.
HCV infection was proven by detecting circulating anti-
HCV antibodies (EIA-2 and RIBA-2, Ortho Diagnostic
Systems, Raritan, NJ, USA) and HCVRNA (AMPLICOR
HCV Test, v2.0. Roche Diagnostics, Alameda, CA, USA).
HCV genotype was determined by a commercial, certified
diagnostic test (VERSANT HCV Genotype 2.0, Siemens
Healthcare Diagnostics, Deerfield, IL, USA). All the
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patients were HCV RNA positive since the ones who had
undergone previous antiviral treatments were non-respon-
ders. In all these latter cases the therapy was stopped at
least 12 months before the diagnosis of cancer and sample
collection.
Liver disease was diagnosed according to standard,
previously described criteria and was based on liver biopsy.
The histopathology of liver samples was assessed by two
independent expert pathologists external to the study, using
the METAVIR algorithm [23].
HCC was diagnosed according to imaging techniques
and/or biopsy [24].
A diagnosis of splenic marginal zone lymphoma
(SMZL), nodal marginal zone lymphoma (NMZL) and
DLBCL was made in nine, four and two NHL patients,
respectively, according to the Revised European American
Lymphoma Classification (REAL) [25].
Methods
Blood sampling was performed at the time of diagnosis of
HCV-related chronic infection, NHL or HCC and before
treatment. PBMCs were isolated from fresh anticoagulated
blood by gradient precipitation on Lymphoprep (Axis-
Shield PoC AS, Oslo, Norway) according to the manu-
facturer’s instructions. After the second wash, the cells
were counted and stored at -80 C.
RNA extraction was performed using Trizol reagent
(Invitrogen, USA) from 5 9 106 PBMCs according to
the manufacturer’s instructions. To monitor extraction
efficiency, C. elegans miR-39 synthetic RNA oligonu-
cleotide (1.1 9 108 copies/106 cells) was added to PBMC
samples and used as external control.
Reverse transcription was done using the TaqMan
MicroRNA RT kit (Applied Biosystems, CA, USA) and
Table 1 Patient main
demographical, laboratory and
clinical data
HS (n = 40) HCV (n = 85) NHL-HCV (n = 15) HCC-HCV (n = 25)
Mean age 39 ± 10.6 54.2 ± 11.9a,b,c 62.5 ± 7.23d,e 71.6 ± 6.54f
Sex (M/F) 22/18 60/25 4/11g,h 16/9
ALT (ULN) 0.65 ± 1.3 1.75 ± 1.26i,l 1.61 ± 0.9m,n 3.86 ± 2.5o
HCV genotype
1 55 8 18
2 15 4 4
3 13 2 3
4 2 1
Viral titer (IU/ml) – 3.6 ± 3.2 3.3 ± 2.8 1.59 ± 3.5p
Histology
F1/F2 69 12 –
F3/F4 16 3 25












Values are expressed as mean ± SD, unless otherwise indicated
ALT alanine transaminase, ULN upper level normal, HS healthy subject, HCV hepatitis C virus, NHL non-
Hodgkin’s lymphoma, HCC hepatocellular carcinoma, IU international units
a HCV versus HS, p\ 0.001; b HCV versus NHL-HCV, p = 0.01; c HCV versus HCC, p\ 0.001; d NHL
versus HS, p\ 0.001; e NHL versus HCC, p\ 0.001; f HCC versus HS, p\ 0.001; g NHL versus HCV,
p = 0.001; h NHL versus HCC, p = 0.022; i HCV versus HS, p\ 0.001; l HCV versus HCC, p\ 0.001;
m NHL versus HS, p = 0.01; n NHL versus HCC, p = 0.006; o HCC versus HS, p\ 0.001; p HCC versus
HCV, p = 0.008
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160 ng of total RNA. Expression levels of human miR-let-
7d, miR-16, miR-21, miR-26b, miR-146a, miR-155 and C.
elegans miR-39 were evaluated by real-time PCR using
specific TaqMan MicroRNA Assays (Applied Biosystems,
CA, USA), according to the manufacturer’s instructions.
Relative expression levels of the different miRNAs were
evaluated with the 2-DCt method, using miR-let-7d as
internal control to normalize miRNA expression levels, as
previously described [22].
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Quantitative variables were analyzed using one-way anal-
ysis of variance (nonparametric ANOVA) or with the t test
for unpaired samples when appropriate. Categorical vari-
ables were analyzed with the v2 test and Fisher’s exact test
when necessary. All tests were two-sided at a 0.05 signif-
icance level. Analyses were performed by Stata v.9.0
(StataCorpLP, College Station, TX, USA).
Results
The main demographical and clinical data of the patients
are reported in Table 1.
As expected, patients in the NHL-HCV and HCC-HCV
groups were older than those in the HCV group (p = 0.01
and p\ 0.001, respectively), with more females in the
NHL-HCV group (NHL-HCV vs. HCV, p = 0.001 and
NHL-HCV vs. HCC-HCV, p = 0.02). There were no sig-
nificant differences in terms of liver disease stage, alanine
aminotransferase (ALT) serum levels or viremia titers
between HCV and NHL-HCV patients, while in the HCC-
HCV group we observed higher ALT levels and lower
HCV titers compared to the HCV group (p\ 0.001 and
p = 0.008, respectively).
There were no significant differences in HCV genotype
distribution among the studied groups.
The expression levels of miR-146a were similar in all
the tested groups, with no significant differences between
patients and controls (Fig. 1).
MiR-16 and miR-155 showed a similar expression
profile: significantly higher levels of these miRNAs were
detected in the PBMCs isolated from NHL-HCV patients
when compared to all other groups. We observed a strong
upregulation of miR-16 in NHL-HCV groups when com-
pared to HS, HCV and HCC-HCV (p\ 0.001; Fig. 2a) and
a higher expression of miR-155 in the PBMCs from NHL
patients when compared to all the other groups (p\ 0.001
NHL-HCV vs. HS and vs. HCC-HCV; p\ 0.01 NHL-
HCV vs. HCV; Fig. 2b).
Interestingly, both miR-26b and miR-21 expression was
altered in patients with HCV-related malignancies. More
specifically, a strong downregulation of miR-26b was
detected in both the HCC and NHL groups when compared
to the HCV and HS groups (p\ 0.001 and p\ 0.05,
respectively; Fig. 3a), while miR-21 resulted in upregula-
tion of the PBMCs from both NHL-HCV and HCC-HCV
patients when compared to the HS and HCV groups (NHL-
HCV vs. HS, NHL vs. HCV, p\ 0.001; HCC-HCV vs.
HS, HCC-HCV vs. HCV, p\ 0.01; Fig. 3b).
Discussion
In this study, we tested the modifications in the expression
pattern of some miRNAs in PBMCs from patients with
HCV-related HCC and NHL. We previously demonstrated
that specific miRNA deregulation in PBMCs occurs in a
smaller group of HCV-positive patients with NHL. Since
interest in peripheral microRNAs as biomarkers is
increasing and promising, we decided to test patients’
serum and the results we obtained were often not repro-
ducible. The main concern about the use of sera in our
subjects was the lack of a reliable and stable miRNA
working as endogenous control. For this reason, as an
alternative choice, we tested the PBMCs, finding this kind
of analysis trustworthy, consistent and easy to perform.
Surprisingly, while performing the new experiments we
observed interesting behavior of some miRNAs in the
Fig. 1 Expression levels of miR-146a in healthy subjects (HS), HCV,
NHL-HCV and HCC-HCV patients
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population of HCV-HCC patients we took as pathological
controls.
We compared these results with data previously
obtained in a group of HCV-positive NHL patients in order
to identify markers of varying evolution for the two
malignancies induced by this infection. We thereby selec-
ted and evaluated a panel of miRNAs shown to be involved
in cancer. As previously described, miR-let-7d was used as
internal control, being the most stable in our cohort of
patients [22, 26].
We previously showed that miR-146a, a misregulated
microRNA in several autoimmune/B-cell disorders, did not
significantly differ in HCV-related lymphoproliferations
compared to controls [22]. Here we report a similar profile
in all the studied groups, including the HCC patients. These
findings suggest that miR-146a is not involved in HCV-
related malignancies and/or altered by the presence of
HCV infection.
MiR-16 and miR-155 showed a similar expression
profile: significantly higher levels of these miRNAs were
Fig. 2 Expression levels of miR-16 (a) and miR-155 (b) in healthy subjects (HS), HCV, NHL-HCV and HCC-HCV patients
Fig. 3 Expression levels of miR-26b (a) and miR-21 (b) in HCV, NHL-HCV and HCC-HCV patients
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detected in the PBMCs isolated from NHL-HCV patients
when compared to all other groups. Since these two miR-
NAs are upregulated in PBMCs of HCV-NHL patients, it is
conceivable they could play a role as biomarkers of HCV-
related hematological malignancy.
Only two previous papers have speculated about the role
of miR-16 expression in HCC: Qu et al. [27] reported
significantly lower levels of this microRNA in the serum of
HCC patients compared to controls, while Zeng et al. [28]
attributed to it the ability of HCC to generate metastasis
through repression of NOTCH signaling cascade. The data
about the miR-16/HCC issue are scarce and conflicting,
and we could not confirm any of the previously described
scenarios since no aberrant expression of miR-16 was
detected in our HCC cohort.
We were unable to attribute some significance to miR-
155 in HCV-related HCC but, as previously reported [22],
its deregulation could indicate an evolution of HCV
chronic infection towards B-cell malignancy. Interestingly,
recent findings correlated miR-155 upregulation with the
detection of the antigenomic strand of HCV in PBMCs
[29]. Since the link between HCV infection of PBMCs and
NHL was described almost 20 years ago [2], it is con-
ceivable that the miRNA-155 upregulation we detected in
HCV-related NHL, but not in HCC and control group
PBMCs, may represent one of the mechanisms of virus-
induced lymphomagenesis.
We noted similar behavior for miR-21 (upregulation)
and miR-26b (downregulation) in both NHL and HCC,
suggesting an involvement of these miRNAs in the infec-
tion-driven oncogenetic process and their role as peripheral
markers for the two HCV-related cancers. MiR-21 was
defined onco-miRNA since its levels were found to be
increased in different malignancies, probably sharing one
or more common pathways involving this specific miRNA
in their pathogenesis [30, 31].
Elevated levels of miR-21 have been previously
demonstrated in both HCC and lymphoma tumor tissue
[14, 16]. Studies conducted in vitro and on HCC tissues
have shown miR-21 to be upregulated, and it was specu-
lated that it decreases the expression of PTEN, a tumor
suppressor, thus promoting cancer cell proliferation,
migration and invasion [14]. A very recent study demon-
strated that this microRNA increases T-lymphocyte sur-
vival in T cell acute lymphoblastic leukemia, mediating its
function, in part via repression of the tumor suppressor
programmed cell-death protein 4 (PDCD4) [32]; this could
be another way through which miR-21 exerts its oncogenic
power.
The increased expression of miR-21 in surgical and
bioptic specimens of HCC has also been associated with
tumor stage and poor prognosis, and miR-21 has emerged
as an independent predictive factor of overall survival in
HCC patients [33]. The literature is rather scarce, and
results are often controversial regarding circulating levels
of this miRNA in HCCs of different etiologies [34–37]. On
the other hand, only two papers have reported increased
levels of miR-21 in serum/plasma samples from lymphoma
patients (DLBCL and primary central nervous system
lymphoma) [38, 39]. In this light, our findings of miR-21
upregulation in PBMCs from HCV-related HCC and NHL
suggest a peripheral detection system more representative
of the tissue tumor profile compared to serum/plasma
analysis. The detection of microRNA levels in PBMCs
could possibly reflect a more stable status compared to
serum: the intracellular environment is certainly more
confined than is serum, which is subjected to a non-stop
systemic exchange of biological molecules. Furthermore, it
is well known that cells circulating in peripheral blood
maintain a resting status that makes this kind of model even
more reliable for the stability of molecular expression
patterns. The utility and accuracy of miRNA analysis in
PBMCs has also been confirmed by previous studies [40–
42]. If confirmed in more numerous cohorts of patients, our
observations about miR-21 in PBMCs could provide new
perspectives for a reliable noninvasive test for both HCV-
related malignancies.
We observed a downregulation of miR-26b in HCV-as-
sociated NHL tissues [16], and we showed the same pattern
in PBMCs isolated from this category of patients [19, 22].
Here we have confirmed previous results in a wider cohort of
lymphoma patients, and, as explained above, driven by
unexpected results in a small HCC group chosen as control,
we tested a group of 25 patients with hepatic cancer and
found statistically significant miR-26b downregulation.
Interestingly, recent studies have demonstrated that
reduced expression of all the members of the miR-26
family (miR-26a-1, miR-26a-2, miR-26b) is correlated
with a higher incidence of HCC and also with poor prog-
nosis [21]. Since the miR-26 levels in liver are higher in
females, these authors postulated a role as tumor suppres-
sor for this miRNA, speculating that this could explain the
varying susceptibility of males to develop HCC. The same
authors showed a paradoxical improvement of overall
survival in patients with lower miR-26 levels in the liver
after adjuvant therapy with interferon-a [21, 43]; this
finding clearly increases interest in identifying miR-26 as a
peripheral biomarker not only of augmented risk and
prognosis, but also as a predictor of therapy response.
The reasons for which the levels of some microRNAs in
the PBMCs of HCC patients seem to reflect the expression
pattern found in the liver tumor tissue are unknown. Fur-
ther studies are needed to analyze PBMCs from surgery
patients and tumor paired samples from HCC patients to
understand the mechanisms underlying these miRNAs’
deregulation.
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Regarding the HCV-positive HCC samples, we per-
formed a statistical analysis to evaluate a possible corre-
lation between miRNA levels and predicted survival terms
obtained by CLIP score. Unfortunately, the number of
patients included in our study did not allow reaching sig-
nificance; therefore, further prospective and dedicated
studies are needed to assess a relationship between miRNA
levels and HCC prognosis.
This study strongly suggests that there is a real possibility
of using the modifications in the miRNA expression pattern
in PBMCs as potential markers of malignancy in chronically
infected HCV patients. Furthermore, since specific miRNAs
are differentially expressed in PBMCs from HCC and NHL
patients, it is conceivable that these microRNAs could also
be useful for understanding the evolution to HCV-related
hepatic or hematological malignancies. Further prospective
studies will help to confirm our results and reveal a transla-
tional application in clinical practice.
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